Antibody data
- Antibody Data
- Antigen structure
- References [19]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 35-5800 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Thymidylate Synthase Monoclonal Antibody (TS 106)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- TS 106
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- -20°C
Submitted references Antiaging gene Klotho regulates epithelial-mesenchymal transition and increases sensitivity to pemetrexed by inducing lipocalin-2 expression.
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells.
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
Translational repression of thymidylate synthase by targeting its mRNA.
Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.
Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
The role of cAMP-dependent signaling in receptor-recognized forms of alpha 2-macroglobulin-induced cellular proliferation.
Takegahara K, Usuda J, Inoue T, Sonokawa T, Matsui T, Matsumoto M
Oncology letters 2021 May;21(5):418
Oncology letters 2021 May;21(5):418
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Kim JY, Shin E, Kim JW, Lee HS, Lee DW, Kim SH, Lee JO, Kim YJ, Kim JH, Bang SM, Ahn SH, Park DJ, Lee JS, Lee JS, Kim HH, Lee KW
PloS one 2015;10(3):e0120324
PloS one 2015;10(3):e0120324
Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC
Journal of surgical oncology 2014 Sep;110(3):302-6
Journal of surgical oncology 2014 Sep;110(3):302-6
The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells.
Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH
Oncotarget 2014 Jun 30;5(12):4170-9
Oncotarget 2014 Jun 30;5(12):4170-9
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013 Apr;8(4):469-77
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013 Apr;8(4):469-77
Translational repression of thymidylate synthase by targeting its mRNA.
Garg D, Beribisky AV, Ponterini G, Ligabue A, Marverti G, Martello A, Costi MP, Sattler M, Wade RC
Nucleic acids research 2013 Apr;41(7):4159-70
Nucleic acids research 2013 Apr;41(7):4159-70
Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.
Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH
Cancer 2012 Feb 15;118(4):1007-13
Cancer 2012 Feb 15;118(4):1007-13
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.
Giudice S, Benassi L, Bertazzoni G, Veratti E, Morini D, Azzoni P, Costi MP, Venturelli A, Pirondi S, Seidenari S, Magnoni C
Investigational new drugs 2012 Aug;30(4):1484-92
Investigational new drugs 2012 Aug;30(4):1484-92
Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.
Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH
Blood 2012 Apr 12;119(15):3561-70
Blood 2012 Apr 12;119(15):3561-70
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH
Cancer chemotherapy and pharmacology 2011 Sep;68(3):743-51
Cancer chemotherapy and pharmacology 2011 Sep;68(3):743-51
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH
British journal of cancer 2010 Sep 7;103(6):845-51
British journal of cancer 2010 Sep 7;103(6):845-51
Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.
Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF
Langenbeck's archives of surgery 2010 Mar;395(3):217-25
Langenbeck's archives of surgery 2010 Mar;395(3):217-25
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Mar 20;28(9):1534-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Mar 20;28(9):1534-9
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Dec 20;27(36):6222-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Dec 20;27(36):6222-8
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S
Acta oncologica (Stockholm, Sweden) 2008;47(6):1046-53
Acta oncologica (Stockholm, Sweden) 2008;47(6):1046-53
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M, Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R
Journal of the National Cancer Institute 2008 Mar 19;100(6):388-98
Journal of the National Cancer Institute 2008 Mar 19;100(6):388-98
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB
European journal of cancer (Oxford, England : 1990) 2008 Jan;44(1):54-60
European journal of cancer (Oxford, England : 1990) 2008 Jan;44(1):54-60
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, Biasco G, Martinelli GN, Roda E, Bazzoli F
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Jun 1;11(11):4234-40
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Jun 1;11(11):4234-40
The role of cAMP-dependent signaling in receptor-recognized forms of alpha 2-macroglobulin-induced cellular proliferation.
Misra UK, Akabani G, Pizzo SV
The Journal of biological chemistry 2002 Sep 27;277(39):36509-20
The Journal of biological chemistry 2002 Sep 27;277(39):36509-20
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of human colon cancer tissue using Ms anti-Thymidylate Synthase (clone TS106) (Product # 35-5800).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6. Western blot analysis for A549 cells and A549/Klotho-1 cells treated with various doses of pemetrexed (0, 0.1 and 0.7 uM) using anti-TS antibody. KL, Klotho; TS, thymidylate synthase.